Company intelligence / Profile preview

S1 Biopharma

New York City, New York, United Statess1biopharma.com ↗

Ownership: Private
Development stage: Other

Overview

S1 Biopharma is a clinical-stage biotech company developing non-hormonal, oral drugs for sexual dysfunction in women and men, notably targeting HSDD and erectile dysfunction. Its most advanced candidate, Lorexys, is a fixed-dose combination of bupropion and trazodone, which acts on multiple brain neurotransmitter systems. The company uses rigorous clinical designs and has completed Phase 2 trials for its lead candidate; no FDA-approved drugs for HSDD exist yet, so S1 Biopharma is addressing a large unmet need[1][4][6].

Therapeutic areas: Men's HealthWomen's HealthPsychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

6 assets

S1B-509

5 more assets in the full pipeline.

Partnerships

Medical advisory board with academic and industry experts[1]Engaged US Capital Global Securities for capital raise[5]

Beyond the preview

Go deeper on S1 Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S1 Biopharma.